Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — H1 FY2018 Earnings Presentation
16 slides from Dr. Lal Pathlabs's earnings presentation, Nov 9, 2017
Slide 1: Dr. Lal PathLabs Limited (DLPL) Q2 & H1 FY18 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q2 & H1 FY18 Results Presentation November 09, 2017
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q2 & H1 FY2018 Financial Performance 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places.
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 189 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,759 Patient Service diagnostic services Centers (PSCs) and 5,021 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralised IT panels
Slide 4: Key Highlights
Key Highlights Performance reflects measures to drive volumes, contain GST impact, manage overall cost structures and enhance productivity During Q2 FY18 : Recorded highest ever revenues of Rs. 2,781 million in Q2 FY18, higher by 6.1% driven by 6.7% volume growth Growth delivered despite hig
Slide 5: Q2 FY18 Financial Performance
Q2 FY18 Financial Performance Particulars (Rs. mn) Q2 FY18 Q2 FY17 Growth % H1 FY18 H1 FY17 Growth % Total Revenue 2,781.0 2,621.7 6.1% 5,273.6 4,850.1 8.7% Total Expenditure 2,002.6 1,821.8 3,840.0 3,444.7 EBITDA 778.4 799.9 -2.7% 1,433.6 1,405.4 2.0% RSU and stock based 28.9 19.5 53.7 26.9 remuner
Slide 6: Financial Highlights
Financial Highlights All figures in Rs. mn Revenues Q2 Revenues improved 6.1% to Rs. 2,781 million underlined by 6.7% 2,622 6% 2,781 volume growth. This was achieved on the back of: • Increase in patients tested YoY together with higher tests per patient • Very high base in the same period of last
Slide 7: Financial Highlights
Financial Highlights All figures in Rs. mn Normalised EBITDA (excl RSU & other stock based remuneration charges) Q2 normalised EBITDA (after eliminating the impact of 819 807 RSU and other stock based remuneration charges) stood slightly lower reflecting operating trends and: • Absorption of GST o
Slide 8: Financial Highlights
Financial Highlights All figures in Rs. mn PBT Q2 PBT stood at Rs. 778.2 million in Q2 vs. Rs. 803.1 million in previous 803 778 year (3%) Q2 PAT at Rs. 510 million in Q2 vs Rs 528.8 million in Q2 last year Q2 FY17 Q2 FY18 H1 PBT grew 2.2% to Rs. 1,438.4 million from Rs. 1,407.9 million last y
Slide 9: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,759 5,668 1,559 4,967 5,021 189 1,340 4,225 172 164 1,064 146 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 No. of patients (mn) No. of samples (mn) 29.3 13.3 26.3 12.0 21.7 9.9 19.0 9.0 17.0 7.6 FY14 FY15 FY16
Slide 10: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “The performance during Q2 captures our focus on realising volume based expansion while containing structural and imposed costs on the model. Backed by strong operational infrastructur
Slide 11: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 12: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 12
Slide 13: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 13
Slide 14: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 15: Experienced Management team
Experienced Management team (Hony) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Bharath Uppiliappan Shankha Banerjee Chief Financial Officer Chief Operating Officer Chief Operatin
Slide 16: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests an